skip to Main Content

Nanoliposomal Irinotecan Could Play a Role in Pancreatic Cancer, But Questions Remain

Newsfeed image, light gray text on dark gray background
The treatment arsenal for pancreatic cancer has been historically limited, with chemotherapy serving as the strongest weapon of choice, according to Jordan D. Berlin, MD; however, now, targeted agents are emerging for certain subsets of patients and a key focus of research has been focused on determining the role of nanoliposomal irinotecan (Onivyde) in the paradigm.

“In terms of chemotherapy, we currently have gemcitabine, nab-paclitaxel [Abraxane], and FOLFIRINOX [leucovorin/5-fluorouracil (5-FU)/irinotecan/oxaliplatin]. However, these therapies are for patients with good performance status; they’re not for all patients,” Berlin explained. “Looking forward, I believe that…there is a potential role for nanoliposomal irinotecan, either in the first-line setting, if the NAPOLI-3 trial turns out positive, or certainly after gemcitabine-based chemotherapy, due to results from the NAPOLI-1 trial. Read more . . . 

Back To Top